Bharat Parenterals Ltd — Important, 17-11-2025: Company Update

Bharat Parenterals Limited reported standalone revenue of Rs. 41.7 Cr for the quarter, influenced by production upgrades and deferred exports, yet gross margins improved to 44.1%. Consolidated revenue was Rs. 64.6 Cr, with gross profit rising 26% and EBITDA turning positive at Rs. 0.8 Cr. A key milestone for its subsidiary, Innoxel Lifesciences, was US FDA approval for its Vadodara facility, paving the way for regulated market supplies. Innoxel secured $1.85 million from new partnerships and aims for operational breakeven this fiscal. Domestic arm Varenyam Healthcare targets Rs. 60-65 Cr revenue, enhancing market presence. New plant construction is underway for Varenyam Bio.